(Reuters) – Eli Lilly Co and privately-held AbCellera Biologics Inc on Thursday announced they would co-develop antibody products for the treatment of COVID-19, a flu-like disease caused by the fast-spreading coronavirus.
AbCellera and Lilly have committed to equally share initial development costs towards a product, the companies said.
Lilly will be responsible for all further development, manufacturing and distribution.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Arun Koyyur)
